Diabetes Drugs Glp1-ra, Dpp4i, and Sglt2i: the Newest Kids on the Block is organized by Dietitian Central. This course has been approved for a maximum of 1.0 Credits

Live Event Date: Jan 07, 2021
Expiration Date: Jan 07, 2024

Target Audience: RDs, DTRs, CDCESs

With an estimated 13% of the adult US population diagnosed with diabetes, dietitians are likely to see an increasing number of patients who need diabetes care. Fortunately, diabetes management technologies are rapidly changing and offering more options. It can be challenging to keep up with the latest drugs, but it is vital to stay well-informed and up-to-date so you can provide the best possible care.

This presentation will cover the three newest classes of diabetes drugs:
• GLP1-RA (glucagon-like peptide-1 receptor agonists): Trulicity, Victoza, Ozempic.
• DPP4i (dipeptidyl peptidase-4 inhibitors): Januvia, Onglyza, Trajenta.
• SGLT2i (sodium/glucose cotransporter-2 inhibitors): Invokana, Farxiga, Jardiance, Steglatro.

In this one-hour webinar, we will review the most important facts about these drugs: how they work, who they work best for, and the pros and cons. This will expand your ability to take on the ever-evolving challenges of diabetes care when working with both fellow practitioners and patients.

Learning Objectives:
Upon successful completion of this one-hour course, the participant should be able to:
• Understand the difference between GLP1-RA and DPP4i drugs.
• Explain the mechanism of action for each of the 3 categories of drugs.
• Describe cautions associated with each of the 3 categories of drugs.
• List the side effects of each of the 3 categories of drugs.






Addressing the Unmet Needs of Patients with Acute Hepatic Porphyria
Oct 03, 2022 - Oct 03, 2023 | Webcast
1.5 AMA PRA Category 1 Credit™ ...
More actions
Obesity in America: Management and Treatment in Children, Adolescents, and Adults
Oct 06, 2022 - Jun 02, 2025 | Text-Based CME
9 Contact Hours
More actions
A Functional Medicine Approach to Hashimoto's Thyroiditis: When Your Patient is Still Symptomatic After Treatment
May 20, 2021 - May 20, 2024 | Webcast
1 Credits
More actions